T cells recognizing tumor antigens presented by MHC molecules on Interferon-producing Killer Dendritic Cells (IKDC) (IKDC-T cell interaction)

This target refers to the functional interaction where T cells are activated by tumor antigens presented on Major Histocompatibility Complex (MHC) molecules by Interferon-producing Killer Dendritic Cells (IKDCs). IKDCs were originally described as a unique immune cell subset in mice (B220+ NK1.1+) that combines the rapid cytotoxicity of Natural Killer (NK) cells with the professional antigen-presenting capabilities of Dendritic Cells (Taieb et al., Nature Medicine, 2006). Upon activation, these cells produce high levels of Type II interferon (IFN-gamma) and can prime both CD4+ and CD8+ T cell responses against tumors (Chan et al., Nature Immunology, 2006). In clinical contexts, the activation of this axis has been observed during treatment with KIT inhibitors like Imatinib, which can enhance the IKDC-mediated anti-tumor response (Zitvogel et al., Nature Reviews Immunology, 2006). However, the existence of IKDCs as a distinct lineage is controversial, as some studies suggest they are transiently activated NK cells that upregulate MHC class II (Vosshenrich et al., Journal of Experimental Medicine, 2007). Despite the nomenclature debate, the biological process of NK-like cells presenting antigens to T cells remains a potent target for immunotherapy. Therapeutic strategies focusing on this interaction aim to bridge innate and adaptive immunity to achieve more effective tumor clearance.

Other names

IKDC-mediated T cell activationInterferon-producing Killer Dendritic Cell-T cell axisAntigen presentation by IKDCsNK-DC hybrid cell interaction

Activation of T cells via MHC-restricted antigen presentation and co-stimulation provided by IKDCs.